Equity Profile

IMNM

Immunome, Inc.

Health CareBiotechnology$3.0B

Nov4Fri

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Immunome, Inc. is a biotechnology company focused on developing innovative therapies for cancer and other diseases using its proprietary antibody discovery platform....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth is crucial for assessing the company's ability to scale its operations and market presence.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

IMNM Q2-2026 Earnings Preview

Context

Company Snapshot

Immunome, Inc. is a biotechnology company focused on developing innovative therapies for cancer and other diseases using its proprietary antibody discovery platform. As part of the health care sector, its advancements could significantly impact treatment options and patient outcomes in the growing field of immunotherapy.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

-68.16%

Avg Stock Reaction

-1.95%

Last Quarter Recap

In Q1 2026, Immunome reported an EPS of -$0.48, beating analyst expectations by 19.46%. However, revenue figures were not disclosed, leaving investors uncertain about overall performance.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, investors are cautious as there are no analyst estimates available, and previous earnings have shown significant volatility. The market is likely looking for any signs of improvement in EPS and revenue growth.

Bull Case

If Immunome can demonstrate strong progress in its drug development pipeline and show improved financial metrics, it could lead to a positive market reaction and increased investor confidence.

Bear Case

Conversely, if the company reports larger-than-expected losses or fails to provide clarity on its revenue generation, it could lead to a sharp decline in stock value.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the updated outlook on the drug pipeline and any upcoming clinical trial results?

Investors will be keen to understand the company's progress in drug development, as this will significantly influence future revenue potential.

How does the company plan to address the recent losses and improve profitability?

Management's strategy for managing costs and enhancing revenue will be critical for investor confidence and stock performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential for Immunome's drug pipeline to yield significant breakthroughs, which could drive revenue growth faster than expected.

Supporting Evidence

The company has a history of surprising on EPS, as seen in recent quarters.

Options pricing suggests a high level of volatility, indicating that traders are anticipating significant news.

The lack of analyst estimates may lead to lower expectations, allowing for a potential positive surprise.

Key Risk

If the company announces a successful trial outcome or a new partnership, it could significantly shift market sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around whether Immunome can demonstrate a path to profitability while advancing its drug pipeline.

Bull Confirmed If

A reported EPS improvement to -$0.30 or better would confirm the bull case and suggest operational progress.

Bear Confirmed If

An EPS worse than -$0.60 would reinforce the bear case and raise concerns about the company's financial health.

Pre-Earnings Positioning

Options Market

Implied Move

±44.3%

Historical Avg

±3.8%

Pricing rich

The options market is pricing in a significant potential move, indicating that traders expect considerable volatility around the earnings report.

Options are pricing ±44.3% while IMNM has averaged ±3.8% over the last 8 prints — setup is pricing rich.

Detail

30d HV

54.2%

Calls (11K)P/C Ratio: 5.31Puts (100)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Immunome beats expectations, history suggests a potential stock increase of around +0.50%, confirming positive sentiment about its future.

In-Line / Cautious

If results are in line with expectations but lack strong guidance, the stock may see muted movement as investors reassess their outlook.

Miss

Should the company miss expectations, history indicates a potential decline of around -3.42%, leading to increased skepticism about its financial trajectory.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the progress of any ongoing clinical trials and their expected timelines.
2Any new partnerships or collaborations that could enhance revenue potential.
3Management's strategy for addressing recent financial losses.
4Insights into market demand for Immunome's therapies and how they plan to capture it.
5Any commentary on regulatory progress or challenges facing the company.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Cirrus Logic, Inc.

Company Snapshot

Immunome, Inc. is a biotechnology company focused on developing innovative therapies for cancer and other diseases using its proprietary antibody discovery platform....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth is crucial for assessing the company's ability to scale its operations and market presence.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

IMNM Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

-68.16%

Avg Stock Reaction

-1.95%

Last Quarter Recap

In Q1 2026, Immunome reported an EPS of -$0.48, beating analyst expectations by 19.46%. However, revenue figures were not disclosed, leaving investors uncertain about overall performance.

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Immunome can demonstrate strong progress in its drug development pipeline and show improved financial metrics, it could lead to a positive market reaction and increased investor confidence.

Bear Case

Conversely, if the company reports larger-than-expected losses or fails to provide clarity on its revenue generation, it could lead to a sharp decline in stock value.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the updated outlook on the drug pipeline and any upcoming clinical trial results?

Investors will be keen to understand the company's progress in drug development, as this will significantly influence future revenue potential.

How does the company plan to address the recent losses and improve profitability?

Management's strategy for managing costs and enhancing revenue will be critical for investor confidence and stock performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential for Immunome's drug pipeline to yield significant breakthroughs, which could drive revenue growth faster than expected.

Supporting Evidence

The company has a history of surprising on EPS, as seen in recent quarters.

Options pricing suggests a high level of volatility, indicating that traders are anticipating significant news.

The lack of analyst estimates may lead to lower expectations, allowing for a potential positive surprise.

Key Risk

If the company announces a successful trial outcome or a new partnership, it could significantly shift market sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around whether Immunome can demonstrate a path to profitability while advancing its drug pipeline.

Bull Confirmed If

A reported EPS improvement to -$0.30 or better would confirm the bull case and suggest operational progress.

Bear Confirmed If

An EPS worse than -$0.60 would reinforce the bear case and raise concerns about the company's financial health.

Pre-Earnings Positioning

Options Market

Implied Move

±44.3%

Historical Avg

±3.8%

Pricing rich

The options market is pricing in a significant potential move, indicating that traders expect considerable volatility around the earnings report.

Options are pricing ±44.3% while IMNM has averaged ±3.8% over the last 8 prints — setup is pricing rich.

Detail

30d HV

54.2%

Calls (11K)P/C Ratio: 5.31Puts (100)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Immunome beats expectations, history suggests a potential stock increase of around +0.50%, confirming positive sentiment about its future.

In-Line / Cautious

If results are in line with expectations but lack strong guidance, the stock may see muted movement as investors reassess their outlook.

Miss

Should the company miss expectations, history indicates a potential decline of around -3.42%, leading to increased skepticism about its financial trajectory.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the progress of any ongoing clinical trials and their expected timelines.
2Any new partnerships or collaborations that could enhance revenue potential.
3Management's strategy for addressing recent financial losses.
4Insights into market demand for Immunome's therapies and how they plan to capture it.
5Any commentary on regulatory progress or challenges facing the company.